An isolated bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody, comprising: a) a first heavy chain (HC1) comprising a HC1 constant domain 3 (HC1 CH3) and a HC1 variable region 1 (VH1); b) a second heavy chain (HC2) comprising a HC2 constant domain 3 (HC2 CH3) and a HC2 variable region 2 (VH2); c) a first light chain (LC1) comprising a light chain variable region 1 (VL1); and d) a second light chain (LC2) comprising a light chain variable region 2 (VL2), wherein the VH1 and the VL1 pair to form a first antigen-binding site that specifically binds EGFR, the VH2 and the VL2 pair to form a second antigen-binding site that specifically binds c-Met, the HC1 comprises at least one substitution in the HC1 CH3 and the HC2 comprises at least one substitution in the HC2 CH3, and the substitution in the HC1 CH3 and the substitution in the HC2 CH3 occur at different amino acid residue positions, when residue numbering is according to the EU index, wherein: i) the VH1 comprises the heavy chain complementarity determining region (HCDR) 1 (HCDR1), HCDR2 and HCDR3 amino acid sequences of SEQ ID NOs: 210, 211 and 212, respectively; and ii) the VL1 comprises the light chain complementarity determining region (LCDR) 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 213, 214 and 215, respectively; and iii) the VH2 comprises the HCDR1, the HCDR2, and the HCDR3 amino acid sequences of SEQ ID NOs: 216, 217 and 218, respectively; and iv) the VL2 comprises the LCDR1, the LCDR2 and the LCDR3 amino acid sequences of SEQ ID NOs: 219, 220 and 221, respectively. a) a first heavy chain (HC1) comprising a HC1 constant domain 3 (HC1 CH3) and a HC1 variable region 1 (VH1); b) a second heavy chain (HC2) comprising a HC2 constant domain 3 (HC2 CH3) and a HC2 variable region 2 (VH2); c) a first light chain (LC1) comprising a light chain variable region 1 (VL1); and d) a second light chain (LC2) comprising a light chain variable region 2 (VL2), wherein the VH1 and the VL1 pair to form a first antigen-binding site that specifically binds EGFR, the VH2 and the VL2 pair to form a second antigen-binding site that specifically binds c-Met, the HC1 comprises at least one substitution in the HC1 CH3 and the HC2 comprises at least one substitution in the HC2 CH3, and the substitution in the HC1 CH3 and the substitution in the HC2 CH3 occur at different amino acid residue positions, when residue numbering is according to the EU index, wherein: i) the VH1 comprises the heavy chain complementarity determining region (HCDR) 1 (HCDR1), HCDR2 and HCDR3 amino acid sequences of SEQ ID NOs: 210, 211 and 212, respectively; and ii) the VL1 comprises the light chain complementarity determining region (LCDR) 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 213, 214 and 215, respectively; and iii) the VH2 comprises the HCDR1, the HCDR2, and the HCDR3 amino acid sequences of SEQ ID NOs: 216, 217 and 218, respectively; and iv) the VL2 comprises the LCDR1, the LCDR2 and the LCDR3 amino acid sequences of SEQ ID NOs: 219, 220 and 221, respectively. i) the VH1 comprises the heavy chain complementarity determining region (HCDR) 1 (HCDR1), HCDR2 and HCDR3 amino acid sequences of SEQ ID NOs: 210, 211 and 212, respectively; and ii) the VL1 comprises the light chain complementarity determining region (LCDR) 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 213, 214 and 215, respectively; and iii) the VH2 comprises the HCDR1, the HCDR2, and the HCDR3 amino acid sequences of SEQ ID NOs: 216, 217 and 218, respectively; and iv) the VL2 comprises the LCDR1, the LCDR2 and the LCDR3 amino acid sequences of SEQ ID NOs: 219, 220 and 221, respectively. <EOS>